Payment overview · 2025
General Payments
$1,138.65
61 reported records · 13 companies
Healthcare provider profile · identity verified
Durga Mulpuri, MD
Allopathic & Osteopathic Physicians|Family Medicine · GROSSE POINTE PARK, MI · NPI 1891786216
Verified facts
What the public records show
CMS Open Payments records show Durga Mulpuri, MD received $1,138.65 in general payments during 2025 across 61 reported records.
Novo Nordisk Inc accounted for 43.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 260 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $494.99 | 43.5% | 26 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $319.69 | 28.1% | 17 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $75.29 | 6.6% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38.72 | 3.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $38.52 | 3.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $34.83 | 3.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.06 | 2.9% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.91 | 2.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.24 | 1.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.11 | 1.5% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.87 | 1.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.81 | 1.3% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $14.61 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,138.65 | 61 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $198.08 | 11 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $139.85 | 7 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $97.60 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $85.18 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $75.29 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $68.97 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $38.72 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $38.52 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $34.83 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.06 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.06 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 131 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 131 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 119 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 73 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
131 | 33 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
119 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
73 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
119 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
68 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
260 | 64 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
131 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 589 | 159 |
| Amlodipine Besylate | Amlodipine Besylate | 588 | 168 |
| Losartan Potassium | Losartan Potassium | 457 | 119 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 390 | 132 |
| Levothyroxine Sodium | Levothyroxine Sodium | 261 | 62 |
| Ozempic | Semaglutide | 260 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 252 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 235 | 61 |
| Omeprazole | Omeprazole | 226 | 66 |
| Carvedilol | Carvedilol | 221 | 63 |
| Metformin Hcl | Metformin Hcl | 211 | 62 |
| Lisinopril | Lisinopril | 189 | 55 |
| Hydralazine Hcl | Hydralazine Hcl | 183 | 49 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 169 | 47 |
| Famotidine | Famotidine | 168 | 49 |
| Furosemide | Furosemide | 165 | 61 |
| Potassium Chloride | Potassium Chloride | 159 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 158 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 153 | 34 |
| Meloxicam | Meloxicam | 145 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 142 | 40 |
| Azithromycin | Azithromycin | 138 | 95 |
| Eliquis | Apixaban | 131 | 24 |
| Farxiga | Dapagliflozin Propanediol | 131 | 33 |
| Allopurinol | Allopurinol | 122 | 27 |
| Jardiance | Empagliflozin | 119 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 117 | 40 |
| Nifedipine Er | Nifedipine | 116 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 115 | 49 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 110 | 30 |
| Alprazolam | Alprazolam | 108 | 35 |
| Januvia | Sitagliptin Phosphate | 108 | 26 |
| Montelukast Sodium | Montelukast Sodium | 107 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 106 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 105 | 47 |
| Alendronate Sodium | Alendronate Sodium | 104 | 28 |
| Methylprednisolone | Methylprednisolone | 103 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 103 | 45 |
| Fluconazole | Fluconazole | 94 | 46 |
| Gabapentin | Gabapentin | 90 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 87 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 85 | 29 |
| Metformin Hcl Er | Metformin Hcl | 83 | 22 |
| Spironolactone | Spironolactone | 82 | 32 |
| Tramadol Hcl | Tramadol Hcl | 81 | 26 |
| Ezetimibe | Ezetimibe | 80 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 80 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 74 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 73 | 20 |
| Simvastatin | Simvastatin | 70 | 22 |
| Trulicity | Dulaglutide | 68 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 68 | 17 |
| Ibuprofen | Ibuprofen | 67 | 24 |
| Methocarbamol | Methocarbamol | 66 | 37 |
| Pregabalin | Pregabalin | 66 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 27 |
| Valacyclovir | Valacyclovir Hcl | 55 | 18 |
| Glipizide Er | Glipizide | 53 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 53 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 52 | 18 |
| Trazodone Hcl | Trazodone Hcl | 51 | 14 |
| Mirtazapine | Mirtazapine | 50 | 12 |
| Hydrocortisone | Hydrocortisone | 49 | 23 |
| Symbicort | Budesonide/Formoterol Fumarate | 48 | suppressed |
| Atenolol | Atenolol | 45 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 37 |
| Ammonium Lactate | Ammonium Lactate | 43 | 20 |
| Cephalexin | Cephalexin | 42 | 35 |
| Enalapril Maleate | Enalapril Maleate | 42 | suppressed |
| Entresto | Sacubitril/Valsartan | 41 | 11 |
| Estradiol | Estradiol | 41 | 15 |
| Chlorthalidone | Chlorthalidone | 40 | 13 |
| Clonidine Hcl | Clonidine Hcl | 39 | suppressed |
| Novolog Flexpen | Insulin Aspart | 39 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 12 |
| Repatha Sureclick | Evolocumab | 38 | suppressed |
| Torsemide | Torsemide | 38 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | 11 |
| Sertraline Hcl | Sertraline Hcl | 37 | 13 |
| Lactulose | Lactulose | 36 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | 11 |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 27 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 31 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 24 |
| Mometasone Furoate | Mometasone Furoate | 31 | 15 |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Ketoconazole | Ketoconazole | 29 | suppressed |
| Levetiracetam | Levetiracetam | 29 | 13 |
| Ondansetron Odt | Ondansetron | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 24 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 28 | 13 |
| Amoxicillin | Amoxicillin | 28 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 22 |
| Colchicine | Colchicine | 27 | 13 |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Klor-Con M20 | Potassium Chloride | 23 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Calcitriol | Calcitriol | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 15 |
| Meclizine Hcl | Meclizine Hcl | 21 | 13 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 11 |
| Naproxen | Naproxen | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Prednisone | Prednisone | 20 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 14 | 14 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,138.65 · 61 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, CONTRAVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, MOUNJARO, OTEZLA, REPATHA, Saxenda, TRELEGY ELLIPTA, Wegovy | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error